Neuralink Stock Price, Valuation & IPO
Private company — Neuralink is privately held. Its shares are not listed on any public exchange and can only be accessed through private secondary transactions.
Status source: AXEVIL investment team
$295.00 per share (AXEVIL consensus estimate)
Source: AXEVIL consensus of recent secondary transactions · as of 1 September 2026
Last round valuation: $9.7B
Source: E, June 2025, post-money
Total raised: $1.2B
Data last updated: 1 October 2026
About Neuralink
Leader in neurochips — brain-computer interfaces for treating neurological disease and enhancing cognition.
Neuralink, founded by Elon Musk, is the leader in implantable brain-computer interfaces: 12 patients control computers and robotic arms by thought, with 15,000+ hours of implant operation and trials in 4 countries. 2026 brings the shift to mass production of implants and fully automated surgery, the launch of Blindsight (vision restoration), and an announced hearing-restoration program. Total addressable market exceeds $400B.
- Sector: Healthcare & Biotech
- Headquarters: Fremont, California
- Founded: 2016
Key highlights
- Mass production in 2026 — an inflection point. Musk announced the shift to high-volume implant production and fully automated surgery. The threads will pass through the dura without removing it — a less invasive procedure, lower risk, and faster recovery.
- Blindsight expands the TAM by an order of magnitude. An FDA Breakthrough Device, with first human trials in Q2 2026, targeting 285 million blind people worldwide. A camera captures the image and sends the signal directly to the visual cortex — starting at Atari-level resolution, with a goal of eventually surpassing natural vision.
- Robotic arms — from digital control to physical control. The CONVOY trial is testing a direct link between the implant and robotic arms. Patients are already eating, putting on a hat, and operating household devices — a direct path to restoring full independence for paralyzed patients.
- A new product — hearing restoration. In April 2026, Neuralink announced a BCI for hearing that bypasses the ear entirely — its third product line after Telepathy and Blindsight. The cochlear implant market is worth $3B, and Neuralink is targeting a much broader audience.
- Four countries, 10K+ applications, a path to FDA approval. Trials are running at UCL Hospitals, Cleveland Clinic Abu Dhabi, and Newcastle Hospitals — international data that speeds up regulatory approval. More than 10,000 ALS patients are already on the waitlist, showing huge demand even before commercialization.
Funding rounds
| Date | Round | Price / share | Post-money valuation |
|---|---|---|---|
| 2 June 2025 | E | $49.09 | $9.7B |
| 22 November 2023 | D | $19.03 | $3.5B |
| 30 July 2021 | C | $13.74 | $2.2B |
| 10 May 2019 | B | $3.82 | $575M |
| 25 August 2017 | A | $1.00 | $143M |
Latest news
Frequently asked questions
How can I buy Neuralink stock before the IPO?
Not on a public exchange — Neuralink is privately held. Shares change hands only in private secondary transactions. AXEVIL structures those as dedicated US special purpose vehicles for accredited investors, subject to availability and to the rules of your jurisdiction.
What is the Neuralink stock price?
A private company has no single official share price. AXEVIL's consensus estimate is $295.00 per share as of 1 September 2026. Its most recent round implied a post-money valuation of $9.7B (June 2025).
What is Neuralink's valuation (net worth)?
Neuralink's most recent funding round valued the company at $9.7B post-money (June 2025) — the latest primary-market measure of what the company is worth. Secondary trades can price its shares above or below that round.
When will Neuralink IPO?
No listing has been announced. AXEVIL does not forecast IPO dates — this page states what has actually been filed or reported, with the date it was last checked.
Is Neuralink publicly traded?
No. Neuralink is a private company and its shares are not listed on any public exchange.
Does Neuralink have a stock symbol?
No. Neuralink has no ticker symbol because its shares are not listed on any exchange; a symbol is assigned only at an IPO or direct listing.
Similar companies
- Altos Labs — Healthcare & Biotech
- Chai Discovery — Healthcare & Biotech
- Benchling — Healthcare & Biotech
- Vercel — Enterprise Software
- Stoke Space — Aerospace
- Saronic — Defense
Risk disclosure
Nothing on this page is an offer to sell or a solicitation to buy any security, and it is not investment advice. Valuations and share prices shown here are AXEVIL estimates built from primary sources — filings, announced rounds and completed secondary transactions — not quoted market prices, and they can be revised. Private-company shares are illiquid, may be impossible to sell, and the entire amount invested can be lost. Availability depends on your jurisdiction and on accredited-investor status.